Zhang et al. found that glycolysis is usually more active in sorafenib-resistant HCC cells than in normal cells; this difference can be attributed to the downregulation of miR-374b expression in HCC cells under continuous sorafenib stimulation, which reduces the inhibitory effects on hnRNPA1. The gene discussed is HNRNPA1; the disease is hepatocellular carcinoma.